Helicobacter pylori antimicrobial resistance rates in the central region of Portugal
- PMID: 24890952
- DOI: 10.1111/1469-0691.12701
Helicobacter pylori antimicrobial resistance rates in the central region of Portugal
Abstract
Helicobacter pylori resistance to antimicrobial agents is steadily increasing. It is extremely important to be aware of the local prevalence of antibiotic resistance so as to adjust treatment strategies. During this single-centre, prospective study, we aimed to determine primary and secondary resistance rates of H. pylori to antibiotics as well as host and bacterial factors associated with this problem. Overall, 180 patients (131 female; mean age 43.4±13.5 years; primary resistance 103; secondary resistance 77) with positive (13) C-urea breath test were submitted to upper endoscopy with gastric biopsies. Helicobacter pylori was cultured and antimicrobial susceptibility was determined by Etest and molecular methods. Clinical and microbiological characteristics associated with resistance were evaluated by logistic regression analysis. Among the 180 isolates 50% were resistant to clarithromycin (primary 21.4%; secondary 88.3%), 34.4% to metronidazole (primary 29.1%; secondary 41.6%), 33.9% to levofloxacin (primary 26.2%; secondary 44.2%), 0.6% to tetracycline and 0.6% to amoxicillin. Being female was an independent predictor of resistance to clarithromycin and metronidazole. Previous, failed, eradication treatments were also associated with a decrease in susceptibility to clarithromycin. History of frequent infections, first-degree relatives with gastric carcinoma and low education levels determined increased resistance to levofloxacin. Mutations in the 23S rRNA and gyrA genes were frequently found in isolates with resistance to clarithromycin and levofloxacin, respectively. This study revealed that resistance rates to clarithromycin, metronidazole and levofloxacin are very high and may compromise H. pylori eradication with first-line and second-line empiric triple treatments in Portugal.
Keywords: Antibiotics; Helicobacter pylori; multidrug resistant; mutations 23S rRNA; mutations gyrA; primary resistance; secondary resistance.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.
Similar articles
-
High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam.Int J Antimicrob Agents. 2015 Mar;45(3):244-8. doi: 10.1016/j.ijantimicag.2014.10.019. Epub 2014 Nov 25. Int J Antimicrob Agents. 2015. PMID: 25499186
-
Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat.Indian J Med Microbiol. 2014 Oct-Dec;32(4):408-13. doi: 10.4103/0255-0857.142256. Indian J Med Microbiol. 2014. PMID: 25297026
-
Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.Helicobacter. 2014 Apr;19(2):90-7. doi: 10.1111/hel.12106. Epub 2014 Feb 10. Helicobacter. 2014. PMID: 24506175
-
Primary Antibiotic Resistance of Helicobacter pylori in China.Dig Dis Sci. 2017 May;62(5):1146-1154. doi: 10.1007/s10620-017-4536-8. Epub 2017 Mar 17. Dig Dis Sci. 2017. PMID: 28315035 Review.
-
Review article: the global emergence of Helicobacter pylori antibiotic resistance.Aliment Pharmacol Ther. 2016 Feb;43(4):514-33. doi: 10.1111/apt.13497. Epub 2015 Dec 23. Aliment Pharmacol Ther. 2016. PMID: 26694080 Free PMC article. Review.
Cited by
-
Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?BMC Gastroenterol. 2017 Feb 15;17(1):31. doi: 10.1186/s12876-017-0589-6. BMC Gastroenterol. 2017. PMID: 28202013 Free PMC article.
-
Multidrug resistance in Helicobacter pylori infection.Front Microbiol. 2023 Feb 27;14:1128497. doi: 10.3389/fmicb.2023.1128497. eCollection 2023. Front Microbiol. 2023. PMID: 36922977 Free PMC article. Review.
-
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries.United European Gastroenterol J. 2024 Nov;12(9):1190-1199. doi: 10.1002/ueg2.12605. Epub 2024 Aug 1. United European Gastroenterol J. 2024. PMID: 39090833 Free PMC article.
-
Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides.Nat Commun. 2021 Apr 15;12(1):2255. doi: 10.1038/s41467-021-22557-7. Nat Commun. 2021. PMID: 33859206 Free PMC article.
-
High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018.Antibiotics (Basel). 2020 May 2;9(5):228. doi: 10.3390/antibiotics9050228. Antibiotics (Basel). 2020. PMID: 32370201 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical